Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

73
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
73
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

93
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
93
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

63
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
63
Genetic Lingo01:11

Genetic Lingo

116.8K
Overview
116.8K
Pleiotropy01:33

Pleiotropy

43.9K
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
43.9K
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

72
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
72

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biallelic ATG9B Variants Define a Novel Autophagy-Related Neurodevelopmental Disorder with Cerebellar Ataxia.

Genes·2026
Same author

Transitional Life Events in Friedreich Ataxia: Differential Age at Onset Perspectives.

Cerebellum (London, England)·2026
Same author

Cerebellar cognitive-affective syndrome in Friedreich Ataxia.

Journal of neurology·2026
Same author

A Patient-Reported Outcome Measure of Communication Difficulties in Friedreich Ataxia: COMATAX.

Cerebellum (London, England)·2026
Same author

A Severity-Agnostic Atrophy Pattern in Spinocerebellar Ataxia Type 3: Volumetrics from ENIGMA-Ataxia.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Early and Progressive Spinal Cord Atrophy in Spinocerebellar Ataxia Type 1.

Movement disorders : official journal of the Movement Disorder Society·2026

Related Experiment Video

Updated: Mar 14, 2026

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
07:08

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

10.1K

COMT Val158Met Polymorphism Modulates Huntington's Disease Progression.

Ruth de Diego-Balaguer1,2,3,4,5,6,7, Catherine Schramm1,2,3, Isabelle Rebeix8,9

  • 1INSERM U955, Equipe 01 Neuropsychologie Interventionnelle, 94000, Créteil, France.

Plos One
|September 23, 2016
PubMed
Summary
This summary is machine-generated.

Genetic factors influence Huntington's disease (HD) progression. The Val158Met polymorphism of the catechol-O-methyltransferase (COMT) gene affects dopamine degradation and impacts cognitive decline in HD patients.

More Related Videos

Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System
10:52

Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System

Published on: December 10, 2021

3.1K
Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice
08:27

Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice

Published on: March 11, 2020

6.7K

Related Experiment Videos

Last Updated: Mar 14, 2026

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
07:08

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

10.1K
Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System
10:52

Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System

Published on: December 10, 2021

3.1K
Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice
08:27

Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice

Published on: March 11, 2020

6.7K

Area of Science:

  • Neurogenetics
  • Neurodegenerative Diseases
  • Pharmacogenetics

Background:

  • Huntington's disease (HD) is a neurodegenerative disorder with poorly understood genetic modifiers.
  • Dopamine system dysfunction is implicated in HD's cognitive deficits, particularly executive functions.
  • The catechol-O-methyltransferase (COMT) gene's Val158Met polymorphism influences dopamine degradation and may affect HD progression.

Purpose of the Study:

  • To investigate the impact of the COMT Val158Met polymorphism on the clinical progression of Huntington's disease.
  • To determine if this genetic variation influences motor, cognitive, behavioral, and functional decline in HD patients.

Main Methods:

  • A prospective, longitudinal, multicenter study involving 438 Huntington's disease gene carriers across various disease stages.
  • Evaluation of motor, cognitive, behavioral, and functional decline using the Unified Huntington's Disease Rating Scale.
  • Genotyping for COMT Val158Met polymorphism and analysis of clinical progression using latent-class mixed models, considering disease duration and CAG repeat length.

Main Results:

  • Huntington's disease gene carriers with fewer CAG repeats and the Val allele of the COMT polymorphism exhibited slower cognitive decline.
  • Met/Met homozygotes showed preserved cognitive capacity in early stages but poorer performance later in the disease compared to Val allele carriers.
  • COMT polymorphism did not significantly affect functional or behavioral progression in Huntington's disease.

Conclusions:

  • The COMT Val158Met polymorphism is a significant genetic factor modulating cognitive progression in Huntington's disease.
  • This finding suggests potential for COMT genotype-based stratification in clinical trials and personalized dopamine-based therapeutic strategies for HD.